Without science there is no future, but without women, there is no future either
En una noche de primavera en Madrid, cinco científicas españolas menores de cuarenta años recibieron reconocimiento por investigaciones que van desde los mecanismos moleculares del cáncer hasta la respuesta de los ecosistemas al cambio climático. El galardón L'Oréal-Unesco, que lleva un cuarto de siglo acompañando a investigadoras en todo el mundo, no solo celebró descubrimientos sino que abrió espacio para nombrar lo que aún falta: estructuras que permitan a las mujeres avanzar en la ciencia sin tener que elegir entre la maternidad y la ambición profesional. Es un recordatorio de que el progreso científico y el progreso social son, en el fondo, la misma tarea.
- Cinco investigadoras presentaron trabajos que podrían transformar el diagnóstico del Parkinson, el tratamiento del cáncer de mama y la conservación de ecosistemas amenazados por el clima.
- La ceremonia en el Teatro Real se convirtió en tribuna inesperada: las galardonadas hablaron con franqueza sobre la fuga de talento femenino cuando la maternidad y la carrera científica colisionan.
- Una de ellas formuló el dilema con precisión quirúrgica: sin ciencia no hay futuro, pero sin mujeres en la ciencia tampoco lo hay.
- El programa lleva desde 1998 intentando corregir una desigualdad que persiste: las mujeres entran a la ciencia en mayor número, pero siguen siendo minoría en los puestos de liderazgo.
- Los 15.000 euros entregados a cada investigadora son un gesto de apoyo, pero las propias premiadas señalan que el verdadero cambio exige transformar los sistemas, no solo visibilizar a quienes los sortean.
Un jueves por la noche, el Teatro Real de Madrid acogió la decimoséptima edición española de los premios L'Oréal-Unesco Para las Mujeres en la Ciencia. Las cinco galardonadas —Patricia González-Rodríguez, Amaia Arruabarrena-Aristorena, Cristina Vieitez, Noelia Ferruz y Nuria Galiana— recibieron 15.000 euros cada una y, sobre todo, un escenario desde el que hablar tanto de sus hallazgos como de los obstáculos que siguen definiendo la trayectoria de las científicas en España.
González-Rodríguez, investigadora en la Universidad de Sevilla, trabaja en la detección temprana del Parkinson y en terapias que puedan frenar su avance antes de que el daño sea irreversible. Arruabarrena-Aristorena, desde la Universidad del País Vasco, estudia reguladores epigenéticos cuyas alteraciones podrían explicar la agresividad del cáncer de mama. Vieitez, en el Instituto de Biología Funcional y Genómica, analiza las histonas —las proteínas que empaquetan el ADN— y cómo sus modificaciones actúan como interruptores moleculares que, cuando fallan, desencadenan enfermedad.
Ferruz, en el Instituto de Biología Molecular de Barcelona, ha entrenado un modelo de inteligencia artificial capaz de generar proteínas nuevas en segundos, una herramienta que podría acelerar tanto el desarrollo de fármacos como la respuesta al cambio climático. Galiana, ecóloga en el Museo Nacional de Ciencias Naturales de Madrid y becaria Marie Curie, investiga cómo responden los ecosistemas al calentamiento global y qué estrategias de conservación resultan más eficaces.
Pero la ceremonia trascendió los laboratorios. Vieitez señaló que muchas jóvenes siguen creyendo que deben elegir entre la ciencia y la maternidad. Arruabarrena-Aristorena contó haber visto a investigadoras talentosas abandonar la carrera al no encontrar un camino viable. La conclusión compartida fue clara: la visibilidad y el apoyo económico son necesarios, pero insuficientes si no cambian las estructuras que hacen necesarios estos premios. Desde 1998, el programa ha respaldado a más de 3.900 investigadoras en más de 110 países; la edición española, activa desde 2006, se enfoca precisamente en los años en que las trayectorias se definen y las presiones se agudizan.
On a Thursday evening at Madrid's Teatro Real, five Spanish scientists took the stage to accept recognition for work that spans some of the most pressing challenges in modern medicine and environmental science. Patricia González-Rodríguez, Amaia Arruabarrena-Aristorena, Cristina Vieitez, Noelia Ferruz, and Nuria Galiana were honored by the L'Oréal-Unesco For Women in Science program, now in its seventeenth year of recognizing female researchers in Spain. Each received 15,000 euros and, more significantly, a platform to discuss not just their discoveries but the structural obstacles that continue to shape women's paths in science.
González-Rodríguez, a junior principal investigator at the University of Seville and its Institute of Biomedicine, is working to understand Parkinson's disease at its earliest stages. The neuroscientist's central challenge is straightforward in its urgency: find ways to diagnose the condition before irreversible damage occurs, then develop therapies that might slow or halt its progression. Her research sits at the intersection of basic neuroscience and clinical need—the kind of work that takes years to yield results but could fundamentally alter how patients experience the disease.
Two of the five honorees focus on protein research and its implications for cancer treatment. Arruabarrena-Aristorena, based at the University of the Basque Country, studies epigenetic regulators—proteins that reshape how our genetic material is packaged and expressed. She hypothesizes that disruptions in these regulators contribute to the development and aggressiveness of breast cancer. Her team has laid groundwork that could eventually lead to clinical trials and new therapeutic options. Vieitez, working at the Institute of Functional Biology and Genomics, takes a complementary approach by examining histones, the proteins that package DNA inside our cells. When histones undergo the right modifications, they function like molecular switches; when those switches malfunction, disease follows. Understanding how to regulate these variations could open new avenues for treating human illness.
Ferruz represents a different frontier. At the Institute of Molecular Biology in Barcelona, she has trained an artificial intelligence model capable of generating novel proteins in seconds—proteins that might be deployed against disease or used to mitigate the effects of climate change. The speed and scale of this approach marks a departure from traditional protein research, suggesting how computational tools are reshaping what's possible in the life sciences.
Galiana's work addresses the broader ecological context. An ecologist at Madrid's National Museum of Natural Sciences, supported by a Marie Curie fellowship from the European Union, she investigates how ecosystems respond to climate change and what conservation strategies might prove most effective. Her research acknowledges that understanding disease and developing treatments happen within a living world that is itself under stress.
What emerged during the awards ceremony, however, extended beyond the science itself. The five researchers spoke candidly about the barriers they and their peers face. Vieitez noted that many young women still believe they must choose between a scientific career and motherhood. Arruabarrena-Aristorena added that she has watched talented women leave research because they saw no viable path to balance family and professional ambition. González-Rodríguez offered a stark formulation: without science there is no future, but without women in science, there is no future either. These statements were not rhetorical flourishes but reflections of a persistent reality—that even as women enter scientific fields in greater numbers, the infrastructure to support their advancement, particularly once they become parents, remains inadequate.
The L'Oréal-Unesco program itself has been working on this problem since 1998, when it began identifying and supporting female researchers across the life sciences and environmental fields. Over twenty-five years, it has backed more than 3,900 researchers from over 110 countries. The Spanish iteration, launched in 2006, targets scientists under forty—the years when career trajectories are being set and when, for many women, the pressure to choose between professional and personal life becomes most acute. The program's persistence suggests that visibility and financial support, while necessary, are not sufficient on their own. The real work lies in changing the systems that make such programs necessary in the first place.
Citas Notables
The current challenge is finding methods to diagnose Parkinson's in its earliest stages, before damage becomes irreversible— Patricia González-Rodríguez
Many young women leave research because they see that balancing family and career is not possible— Amaia Arruabarrena-Aristorena
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that these five scientists are women? Isn't the research what counts?
The research absolutely counts—that's why they won. But the fact that they're women matters because women are systematically underrepresented in senior positions in science, and because the barriers they face are structural, not individual. When five accomplished researchers all mention the same problem—that motherhood and career feel incompatible—that's not coincidence. It's a system that wasn't built with them in mind.
What's the actual obstacle? Is it that labs don't hire mothers, or something else?
It's more subtle and pervasive than that. It's the expectation that you'll be available at all hours, that you'll relocate for postdocs, that you'll prioritize the lab over everything else. Those norms were written when most scientists were men with partners at home managing everything else. When women enter that system, they hit a wall that men often don't see.
So the award itself—does it change anything?
It changes visibility and it provides resources. Fifteen thousand euros is real money for research. But more importantly, it creates a moment where these scientists can speak publicly about what they're experiencing. That conversation matters. It signals that the problem is real and worth addressing.
What about the research itself? What's the most significant work here?
Probably the protein research. If Arruabarrena-Aristorena and Vieitez can identify which protein modifications drive cancer, that could lead to entirely new treatments. And Ferruz's AI approach—generating novel proteins in seconds—that's genuinely transformative. It suggests we're moving into a phase where computational tools can do things we couldn't do before.
And the ecology work—how does that fit?
It's the reminder that all of this happens in a world that's changing. Galiana's work on how ecosystems respond to climate change is foundational. You can develop the best cancer drug in the world, but if the ecosystems that support human life are destabilizing, the context for everything else shifts. She's working on the larger frame.